Lauris has a strong science background with a degree in Immunology and Biochemistry; and a PhD and 6 years post-doctoral experience covering cell expression systems, protein purification, mass spectrometry, protein crystallography and bioinformatics. Her patent work reflects this broad base.
Lauris is particularly adept with difficult patent cases, both European and US, getting important grants with commercially useful claims for clients. This includes European opposition cases where her attention to detail and tenacity are core to her success.
Having worked with many US in-house counsels including those in the food industry, DNA sequencing technology, microbiome bioinformatics and antibody therapies to draft applications and manage large European and global portfolios, Lauris knows how to best assist in-house counsel. She adapts her way of working to whatever fits best with the way the in-house team likes to work, effectively becoming another member of the team.
She uses this proactive approach in assisting all her clients and is known for being on the telephone often to establish a rapport with the client to understand their science and how to guide them commercially.
Immunology and Biochemistry
By Managing IP
May 10th 2022
March 9th 2021
January 14th 2021
November 17th 2020
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.